Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2011 | 1 |
2013 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening.
Med Care. 2013 Apr;51(4):295-300. doi: 10.1097/MLR.0b013e31827da979.
Med Care. 2013.
PMID: 23269114
Free PMC article.
Clinical Trial.
RESULTS: Screening plausibly explains 45% and changes in primary treatment can explain 33% of the US prostate cancer mortality decline. Extrapolating the ERSPC results to the long-term US setting implies an absolute mortality reduction at least 5 times greater than that ob …
RESULTS: Screening plausibly explains 45% and changes in primary treatment can explain 33% of the US prostate cancer mortality decline. Extr …
Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates.
Gulati R, Mariotto AB, Chen S, Gore JL, Etzioni R.
Gulati R, et al.
J Clin Epidemiol. 2011 Dec;64(12):1412-7. doi: 10.1016/j.jclinepi.2011.06.011.
J Clin Epidemiol. 2011.
PMID: 22032753
Free PMC article.
OBJECTIVE: To project long-term estimates of the number needed to screen (NNS) and the additional number needed to treat (NNT) to prevent one prostate cancer death with prostate-specific antigen (PSA) screening in Europe and in the United States. ...Corresponding estimates …
OBJECTIVE: To project long-term estimates of the number needed to screen (NNS) and the additional number needed to treat (NNT) to pre …
Item in Clipboard
Cite
Cite